In premarketing trials involving more than 5400 patients and/or normal subjects, accidental or intentional overdosage of oral ziprasidone was documented in 10 patients. All of these patients survived without sequelae. In the patient taking the largest confirmed amount, 3,240 mg, the only symptoms reported were minimal sedation, slurring of speech, and transitory hypertension (200/95). Adverse reactions reported with ziprasidone overdose included extrapyramidal symptoms, somnolence, tremor, and anxiety.
Management Of OverdosageIn case of acute overdosage, establish and maintain an airway and ensure adequate oxygenation and ventilation. Intravenous access should be established, and gastric lavage (after intubation, if patient is unconscious) and administration of activated charcoal together with a laxative should be considered. The possibility of obtundation, seizure, or dystonic reaction of the head and neck following overdose may create a risk of aspiration with induced emesis.
Cardiovascular monitoring should commence immediately and should include continuous electrocardiographic monitoring to detect possible arrhythmias. If antiarrhythmic therapy is administered, disopyramide, procainamide, and quinidine carry a theoretical hazard of additive QTprolonging effects that might be additive to those of ziprasidone.
Hypotension and circulatory collapse should be treated with appropriate measures such as intravenous fluids. If sympathomimetic agents are used for vascular support, epinephrine and dopamine should not be used, since beta stimulation combined with α antagonism associated with ziprasidone may worsen hypotension. Similarly, it is reasonable to expect that the alpha-adrenergic-blocking properties of bretylium might be additive to those of ziprasidone, resulting in problematic hypotension.
In cases of severe extrapyramidal symptoms, anticholinergic medication should be administered. There is no specific antidote to ziprasidone, and it is not dialyzable. The possibility of multiple drug involvement should be considered. Close medical supervision and monitoring should continue until the patient recovers.
Because of ziprasidone's dose-related prolongation of the QT interval and the known association of fatal arrhythmias with QT prolongation by some other drugs, ziprasidone is contraindicated:
Pharmacokinetic/pharmacodynamic studies between ziprasidone and other drugs that prolong the QT interval have not been performed. An additive effect of ziprasidone and other drugs that prolong the QT interval cannot be excluded. Therefore, ziprasidone should not be given with:
Ziprasidone is contraindicated in individuals with a known hypersensitivity to the product.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Clinical trials for oral ziprasidone included approximately 5700 patients and/or normal subjects exposed to one or more doses of ziprasidone. Of these 5700, over 4800 were patients who participated in multiple-dose effectiveness trials, and their experience corresponded to approximately 1831 patientyears. These patients include: (1) 4331 patients who participated in multiple-dose trials, predominantly in schizophrenia, representing approximately 1698 patient-years of exposure as of February 5, 2000; and (2) 472 patients who participated in bipolar mania trials representing approximately 133 patient-years of exposure. An additional 127 patients with bipolar disorder participated in a long-term maintenance treatment study representing approximately 74.7 patient-years of exposure to ziprasidone. The conditions and duration of treatment with ziprasidone included open-label and double-blind studies, inpatient and outpatient studies, and short-term and longer-term exposure.
Clinical trials for intramuscular ziprasidone included 570 patients and/or normal subjects who received one or more injections of ziprasidone. Over 325 of these subjects participated in trials involving the administration of multiple doses.
Adverse reactions during exposure were obtained by collecting voluntarily reported adverse experiences, as well as results of physical examinations, vital signs, weights, laboratory analyses, ECGs, and results of ophthalmologic examinations.
The stated frequencies of adverse reactions represent the proportion of individuals who experienced, at least once, a treatment-emergent adverse reaction of the type listed. A reaction was considered treatment emergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation.
Adverse Findings Observed In Short-Term, Placebo-Controlled Trials With Oral ZiprasidoneThe following findings are based on the short-term placebo-controlled premarketing trials for schizophrenia (a pool of two 6-week, and two 4-week fixed-dose trials) and bipolar mania (a pool of two 3-week flexible-dose trials) in which ziprasidone was administered in doses ranging from 10 to 200 mg/day.
Commonly Observed Adverse Reactions In Short Term-Placebo-Controlled TrialsThe following adverse reactions were the most commonly observed adverse reactions associated with the use of ziprasidone (incidence of 5% or greater) and not observed at an equivalent incidence among placebo-treated patients (ziprasidone incidence at least twice that for placebo):
Schizophrenia Trials (see Table 11)
Bipolar Trials (see Table 12)
Approximately 4.1% (29/702) of ziprasidone-treated patients in short-term, placebo-controlled studies discontinued treatment due to an adverse reaction, compared with about 2.2% (6/273) on placebo. The most common reaction associated with dropout was rash, including 7 dropouts for rash among ziprasidone patients (1%) compared to no placebo patients.
Adverse Reactions Occurring At An Incidence Of 2% or More Among Ziprasidone-Treated Patients In Short-Term, Oral, Placebo-Controlled TrialsTable 11 enumerates the incidence, rounded to the nearest percent, of treatment-emergent adverse reactions that occurred during acute therapy (up to 6 weeks) in predominantly patients with schizophrenia, including only those reactions that occurred in 2% or more of patients treated with ziprasidone and for which the incidence in patients treated with ziprasidone was greater than the incidence in placebo-treated patients.
Table 11: Treatment-Emergent Adverse Reaction Incidence In Short-Term Oral Placebo-Controlled Trials – Schizophrenia
| Body System/ Adverse Reaction | Percentage of Patients Reporting Reaction | |
| Ziprasidone (N=702) | Placebo (N=273) | |
| Body as a Whole | ||
| Asthenia | 5 | 3 |
| Accidental Injury | 4 | 2 |
| Chest Pain | 3 | 2 |
| Cardiovascular | ||
| Tachycardia | 2 | 1 |
| Digestive | ||
| Nausea | 10 | 7 |
| Constipation | 9 | 8 |
| Dyspepsia | 8 | 7 |
| Diarrhea | 5 | 4 |
| Dry Mouth | 4 | 2 |
| Anorexia | 2 | 1 |
| Nervous | ||
| Extrapyramidal Symptoms* | 14 | 8 |
| Somnolence | 14 | 7 |
| Akathisia | 8 | 7 |
| Dizziness † | 8 | 6 |
| Respiratory | ||
| Respiratory Tract Infection | 8 | 3 |
| Rhinitis | 4 | 2 |
| Cough Increased | 3 | 1 |
| Skin and Appendages | ||
| Rash | 4 | 3 |
| Fungal Dermatitis | 2 | 1 |
| Special Senses | ||
| Abnormal Vision | 3 | 2 |
| *Extrapyramidal Symptoms includes the following adverse reaction terms: extrapyramidal syndrome, hypertonia, dystonia, dyskinesia, hypokinesia, tremor, paralysis and twitching. None of these adverse reactions occurred individually at an incidence greater than 5% in schizophrenia trials. †Dizziness includes the adverse reaction terms dizziness and lightheadedness. | ||
An analysis for dose response in the schizophrenia 4-study pool revealed an apparent relation of adverse reaction to dose for the following reactions: asthenia, postural hypotension, anorexia, dry mouth, increased salivation, arthralgia, anxiety, dizziness, dystonia, hypertonia, somnolence, tremor, rhinitis, rash, and abnormal vision.
Extrapyramidal Symptoms (EPS) - The incidence of reported EPS (which included the adverse reaction terms extrapyramidal syndrome, hypertonia, dystonia, dyskinesia, hypokinesia, tremor, paralysis and twitching) for ziprasidone-treated patients in the short-term, placebo-controlled schizophrenia trials was 14% vs. 8% for placebo. Objectively collected data from those trials on the Simpson-Angus Rating Scale (for EPS) and the Barnes Akathisia Scale (for akathisia) did not generally show a difference between ziprasidone and placebo.
Dystonia - Class Effect: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs. An elevated risk of acute dystonia is observed in males and younger age groups.
Vital Sign Changes - Ziprasidone is associated with orthostatic hypotension
ECG Changes - Ziprasidone is associated with an increase in the QTc interval. In the schizophrenia trials, ziprasidone was associated with a mean increase in heart rate of 1.4 beats per minute compared to a 0.2 beats per minute decrease among placebo patients.
Other Adverse Reactions Observed During The Premarketing Evaluation Of Oral ZiprasidoneFollowing is a list of COSTART terms that reflect treatment-emergent adverse reactions as defined in the introduction to the ADVERSE REACTIONS section reported by patients treated with ziprasidone in schizophrenia trials at multiple doses > 4 mg/day within the database of 3834 patients. All reported reactions are included except those already listed in Table 11 or elsewhere in labeling, those reaction terms that were so general as to be uninformative, reactions reported only once and that did not have a substantial probability of being acutely life-threatening, reactions that are part of the illness being treated or are otherwise common as background reactions, and reactions considered unlikely to be drugrelated. It is important to emphasize that, although the reactions reported occurred during treatment with ziprasidone, they were not necessarily caused by it.
Adverse reactions are further categorized by body system and listed in order of decreasing frequency according to the following definitions:
Frequent - adverse reactions occurring in at least 1/100 patients ( ≥ 1.0% of patients) (only those not already listed in the tabulated results from placebo-controlled trials appear in this listing);
Infrequent - adverse reactions occurring in 1/100 to 1/1000 patients (in 0.1-1.0% of patients)
Rare - adverse reactions occurring in fewer than 1/1000 patients ( < 0.1% of patients).
Body as a Wholeabdominal pain, flu syndrome, fever, accidental fall, face edema,
Frequent chills, photosensitivity reaction, flank pain, hypothermia, motor vehicle accident
Cardiovascular SystemFrequent tachycardia, hypertension, postural hypotension
Infrequent bradycardia, angina pectoris, atrial fibrillation first degree AV block, bundle branch block, phlebitis, pulmonary
Rare embolus, cardiomegaly, cerebral infarct, cerebrovascular accident, deep thrombophlebitis, myocarditis, thrombophlebitis
Digestive SystemFrequent anorexia, vomiting
Infrequent rectal hemorrhage, dysphagia, tongue edema
Rare gum hemorrhage, jaundice, fecal impaction, gamma glutamyl transpeptidase increased, hematemesis, cholestatic jaundice, hepatitis, hepatomegaly, leukoplakia of mouth, fatty liver deposit, melena
Endocrine
Rare hypothyroidism, hyperthyroidism, thyroiditis
Hemic and Lymphatic SystemInfrequent anemia, ecchymosis, leukocytosis, leukopenia, eosinophilia, lymphadenopathy
Rare thrombocytopenia, hypochromic anemia, lymphocytosis, monocytosis, basophilia, lymphedema, polycythemia, thrombocythemia
Metabolic and Nutritional DisordersInfrequent thirst, transaminase increased, peripheral edema, hyperglycemia, creatine phosphokinase increased, alkaline phosphatase increased, hypercholesteremia, dehydration, lactic dehydrogenase increased, albuminuria, hypokalemia
Rare BUN increased, creatinine increased, hyperlipemia, hypocholesteremia, hyperkalemia, hypochloremia, hypoglycemia, hyponatremia, hypoproteinemia, glucose tolerance decreased, gout, hyperchloremia, hyperuricemia, hypocalcemia, hypoglycemicreaction, hypomagnesemia, ketosis, respiratory alkalosis
Musculoskeletal SystemFrequent myalgia
Infrequent tenosynovitis
Rare myopathy
Nervous SystemFrequent agitation, extrapyramidal syndrome, tremor, dystonia, hypertonia, dyskinesia, hostility, twitching, paresthesia, confusion, vertigo, hypokinesia, hyperkinesia, abnormal gait, oculogyric crisis, hypesthesia, ataxia, amnesia, cogwheel rigidity, delirium, hypotonia, akinesia, dysarthria, withdrawal syndrome, buccoglossal syndrome, choreoathetosis, diplopia, incoordination, neuropathy
Infrequent paralysis
Rare myoclonus, nystagmus, torticollis, circumoral paresthesia, opisthotonos, reflexes increased, trismus
Respiratory SystemFrequent dyspnea
Infrequent pneumonia, epistaxis
Rare hemoptysis, laryngismus
Skin and AppendagesInfrequent maculopapular rash, urticaria, alopecia, eczema, exfoliative dermatitis, contact dermatitis, vesiculobullous rash
Special SensesFrequent fungal dermatitis
Infrequent conjunctivitis, dry eyes, tinnitus, blepharitis, cataract, photophobia
Rare eye hemorrhage, visual field defect, keratitis, keratoconjunctivitis
Urogenital SystemInfrequent impotence, abnormal ejaculation, amenorrhea, hematuria, menorrhagia, female lactation, polyuria, urinary retention metrorrhagia, male sexual dysfunction, anorgasmia, glycosuria
Rare gynecomastia, vaginal hemorrhage, nocturia, oliguria, female sexual dysfunction, uterine hemorrhage
Bipolar Disorder Acute Treatment of Manic or Mixed Episodes Adverse Reactions Associated With Discontinuation Of Treatment In Short Term, Placebo-Controlled TrialsApproximately 6.5% (18/279) of ziprasidone-treated patients in short-term, placebo-controlled studies discontinued treatment due to an adverse reaction, compared with about 3.7% (5/136) on placebo. The most common reactions associated with dropout in the ziprasidone-treated patients were akathisia, anxiety, depression, dizziness, dystonia, rash and vomiting, with 2 dropouts for each of these reactions among ziprasidone patients (1%) compared to one placebo patient each for dystonia and rash (1%) and no placebo patients for the remaining adverse reactions.
Adverse Reactions Occurring At An Incidence Of 2% Or More Among Ziprasidone-Treated Patients In Short-Term, Oral, Placebo-Controlled TrialsTable 12 enumerates the incidence, rounded to the nearest percent, of treatment-emergent adverse reactions that occurred during acute therapy (up to 3 weeks) in patients with bipolar mania, including only those reactions that occurred in 2% or more of patients treated with ziprasidone and for which the incidence in patients treated with ziprasidone was greater than the incidence in placebo-treated patients.
Table 12: Treatment-Emergent Adverse Reactions Incidence In Short-Term Oral Placebo-Controlled Trials - Manic and Mixed Episodes Associated with Bipolar Disorder
| Body System/ Adverse Reaction | Percentage of Patients Reporting Reaction | Placebo (N=136) |
| Ziprasidone (N=279) | ||
| Body as a Whole | ||
| Headache | 18 | 17 |
| Asthenia | 6 | 2 |
| Accidental Injury | 4 | 1 |
| Cardiovascular | ||
| Hypertension | 3 | 2 |
| Digestive | ||
| Nausea | 10 | 7 |
| Diarrhea | 5 | 4 |
| Dry Mouth | 5 | 4 |
| Vomiting | 5 | 2 |
| Increased Salivation | 4 | 0 |
| Tongue Edema | 3 | 1 |
| Dysphagia | 2 | 0 |
| Musculoskeletal | ||
| Myalgia | 2 | 0 |
| Nervous | ||
| Somnolence | 31 | 12 |
| Extrapyramidal Symptoms* | 31 | 12 |
| Dizziness † | 16 | 7 |
| Akathisia | 10 | 5 |
| Anxiety | 5 | 4 |
| Hypesthesia | 2 | 1 |
| Speech Disorder | 2 | 0 |
| Respiratory | ||
| Pharyngitis | 3 | 1 |
| Dyspnea | 2 | 1 |
| Skin and Appendages | ||
| Fungal Dermatitis | 2 | 1 |
| Special Senses | ||
| Abnormal Vision | 6 | 3 |
| *Extrapyramidal Symptoms includes the following adverse reaction terms: extrapyramidal syndrome, hypertonia, dystonia, dyskinesia, hypokinesia, tremor, paralysis and twitching. None of these adverse reactions occurred individually at an incidence greater than 10% in bipolar mania trials. †Dizziness includes the adverse reaction terms dizziness and lightheadedness. | ||
Explorations for interactions on the basis of gender did not reveal any clinically meaningful differences in the adverse reaction occurrence on the basis of this demographic factor.
Intramuscular Ziprasidone Adverse Reactions Occurring At An Incidence Of 1% Or More Among Ziprasidone-Treated Patients In Short-Term Trials Of Intramuscular ZiprasidoneTable 13 enumerates the incidence, rounded to the nearest percent, of treatment-emergent adverse reactions that occurred during acute therapy with intramuscular ziprasidone in 1% or more of patients.
In these studies, the most commonly observed adverse reactions associated with the use of intramuscular ziprasidone (incidence of 5% or greater) and observed at a rate on intramuscular ziprasidone (in the higher dose groups) at least twice that of the lowest intramuscular ziprasidone group were headache (13%), nausea (12%), and somnolence (20%).
Table 13: Treatment-Emergent Adverse Reaction Incidence In Short-Term Fixed-Dose Intramuscular Trials
| Body System/ Adverse Reaction | Percentage of Patients Reporting Reaction | ||
| Ziprasidone 2 mg (N=92) | Ziprasidone 10 mg (N=63) | Ziprasidone 20 mg (N=41) | |
| Body as a Whole | |||
| Headache | 3 | 13 | 5 |
| Injection Site Pain | 9 | 8 | 7 |
| Asthenia | 2 | 0 | 0 |
| Abdominal Pain | 0 | 2 | 0 |
| Flu Syndrome | 1 | 0 | 0 |
| Back Pain | 1 | 0 | 0 |
| Cardiovascular | |||
| Postural Hypotension | 0 | 0 | 5 |
| Hypertension | 2 | 0 | 0 |
| Bradycardia | 0 | 0 | 2 |
| Vasodilation | 1 | 0 | 0 |
| Digestive | |||
| Nausea | 4 | 8 | 12 |
| Rectal Hemorrhage | 0 | 0 | 2 |
| Diarrhea | 3 | 3 | 0 |
| Vomiting | 0 | 3 | 0 |
| Dyspepsia | 1 | 3 | 2 |
| Anorexia | 0 | 2 | 0 |
| Constipation | 0 | 0 | 2 |
| Tooth Disorder | 1 | 0 | 0 |
| Dry Mouth | 1 | 0 | 0 |
| Nervous | |||
| Dizziness | 3 | 3 | 10 |
| Anxiety | 2 | 0 | 0 |
| Insomnia | 3 | 0 | 0 |
| Somnolence | 8 | 8 | 20 |
| Akathisia | 0 | 2 | 0 |
| Agitation | 2 | 2 | 0 |
| Extrapyramidal Syndrome | 2 | 0 | 0 |
| Hypertonia | 1 | 0 | 0 |
| Cogwheel Rigidity | 1 | 0 | 0 |
| Paresthesia | 0 | 2 | 0 |
| Personality Disorder | 0 | 2 | 0 |
| Psychosis | 1 | 0 | 0 |
| Speech Disorder | 0 | 2 | 0 |
| Respiratory | |||
| Rhinitis | 1 | 0 | 0 |
| Skin and Appendages | |||
| Furunculosis | 0 | 2 | 0 |
| Sweating | 0 | 0 | 2 |
| Urogenital | |||
| Dysmenorrhea | 0 | 2 | 0 |
| Priapism | 1 | 0 | 0 |
The following adverse reactions have been identified during post approval use of Zeldox. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Adverse reaction reports not listed above that have been received since market introduction include rare occurrences of the following : Cardiac Disorders: Tachycardia, torsade de pointes (in the presence of multiple confounding factors), ; Digestive System Disorders: Swollen Tongue; Reproductive System and Breast Disorders: Galactorrhea, priapism; Nervous System Disorders: Facial Droop, neuroleptic malignant syndrome, serotonin syndrome (alone or in combination with serotonergic medicinal products), tardive dyskinesia; Psychiatric Disorders: Insomnia, mania/hypomania; Skin and subcutaneous Tissue Disorders: Allergic reaction (such as allergic dermatitis, angioedema, orofacial edema, urticaria), rash, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS); Urogenital System Disorders: Enuresis, urinary incontinence; Vascular Disorders: Postural hypotension, syncope.
Zeldox is indicated for the treatment of schizophrenia, as monotherapy for the acute treatment of bipolar manic or mixed episodes, and as an adjunct to lithium or valproate for the maintenance treatment of bipolar disorder. Zeldox intramuscular is indicated for acute agitation in schizophrenic patients. When deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone's greater capacity to prolong the QT/QTc interval compared to several other antipsychotic drugs. Prolongation of the QTc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death. In many cases this would lead to the conclusion that other drugs should be tried first. Whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known
SchizophreniaZeldox is indicated for the treatment of schizophrenia. The efficacy of oral ziprasidone was established in four short-term (4- and 6-week) controlled trials of adult schizophrenic inpatients and in one maintenance trial of stable adult schizophrenic inpatients.
Bipolar I Disorder (Acute Mixed or Manic Episodes And Maintenance Treatment As An Adjunct To Lithium Or Valproate)Zeldox is indicated as monotherapy for the acute treatment of manic or mixed episodes associated with bipolar I disorder. Efficacy was established in two 3-week monotherapy studies in adult patients.
Zeldox is indicated as an adjunct to lithium or valproate for the maintenance treatment of bipolar I disorder. Efficacy was established in a maintenance trial in adult patients. The efficacy of Zeldox as monotherapy for the maintenance treatment of bipolar I disorder has not been systematically evaluated in controlled clinical trials.
Acute Treatment Of Agitation In SchizophreniaZeldox intramuscular is indicated for the treatment of acute agitation in schizophrenic patients for whom treatment with ziprasidone is appropriate and who need intramuscular antipsychotic medication for rapid control of agitation. The efficacy of intramuscular ziprasidone for acute agitation in schizophrenia was established in single day controlled trials of agitated schizophrenic inpatients
“Psychomotor agitation” is defined in DSM-IV as “excessive motor activity associated with a feeling of inner tension”. Schizophrenic patients experiencing agitation often manifest behaviors that interfere with their diagnosis and care, e.g., threatening behaviors, escalating or urgently distressing behavior, or self-exhausting behavior, leading clinicians to the use of intramuscular antipsychotic medications to achieve immediate control of the agitation.
Since there is no experience regarding the safety of administering ziprasidone intramuscular to schizophrenic patients already taking oral ziprasidone, the practice of co-administration is not recommended.
Ziprasidone intramuscular is intended for intramuscular use only and should not be administered intravenously.
Ziprasidone exhibited high in vitro binding affinity for the dopamine D2 and D3, the serotonin 5HT2A, 5HT2C, 5HT1A, 5HT1D, and α1 -adrenergic receptors (Ki s of 4.8, 7.2, 0.4, 1.3, 3.4, 2, and 10 nM, respectively), and moderate affinity for the histamine H1 receptor (Ki =47 nM). Ziprasidone functioned as an antagonist at the D2, 5HT2D, and 5HT1D receptors, and as an agonist at the 5HT1A receptor. Â Ziprasidone inhibited synaptic reuptake of serotonin and norepinephrine. No appreciable affinity was exhibited for other receptor/binding sites tested, including the cholinergic muscarinic receptor (IC > 1 μM). Antagonism at receptors other than dopamine and 5HT2 with similar receptor affinities may explain some of the other therapeutic and side effects of ziprasidone. Ziprasidone's antagonism of histamine H1 receptors may explain the somnolence observed with this drug. Ziprasidone's antagonism of α -adrenergic receptors may explain the orthostatic hypotension observed with this drug.
Ziprasidone's activity is primarily due to the parent drug. The multiple-dose pharmacokinetics of ziprasidone are dose-proportional within the proposed clinical dose range, and ziprasidone accumulation is predictable with multiple dosing. Elimination of ziprasidone is mainly via hepatic metabolism with a mean terminal half-life of about 7 hours within the proposed clinical dose range. Steady-state concentrations are achieved within one to three days of dosing. The mean apparent systemic clearance is 7.5 mL/min/kg. Ziprasidone is unlikely to interfere with the metabolism of drugs metabolized by cytochrome P450 enzymes.
AbsorptionZiprasidone is well absorbed after oral administration, reaching peak plasma concentrations in 6 to 8 hours. The absolute bioavailability of a 20 mg dose under fed conditions is approximately 60%. The absorption of ziprasidone is increased up to two-fold in the presence of food.
DistributionZiprasidone has a mean apparent volume of distribution of 1.5 L/kg. It is greater than 99% bound to plasma proteins, binding primarily to albumin and α -acid glycoprotein. The in vitro plasma protein binding of ziprasidone was not altered by warfarin or propranolol, two highly protein-bound drugs, nor did ziprasidone alter the binding of these drugs in human plasma. Thus, the potential for drug interactions with ziprasidone due to displacement is minimal.
Metabolism And EliminationZiprasidone is extensively metabolized after oral administration with only a small amount excreted in the urine ( < 1%) or feces ( < 4%) as unchanged drug. Ziprasidone is primarily cleared via three metabolic routes to yield four major circulating metabolites, benzisothiazole (BITP) sulphoxide, BITP-sulphone, ziprasidone sulphoxide, and S-methyldihydroziprasidone. Approximately 20% of the dose is excreted in the urine, with approximately 66% being eliminated in the feces. Unchanged ziprasidone represents about 44% of total drug-related material in serum. In vitro studies using human liver subcellular fractions indicate that S-methyldihydroziprasidone is generated in two steps. These studies indicate that the reduction reaction is mediated primarily by chemical reduction by glutathione as well as by enzymatic reduction by aldehyde oxidase and the subsequent methylation is mediated by thiol methyltransferase. In vitro studies using human liver microsomes and recombinant enzymes indicate that CYP3A4 is the major CYP contributing to the oxidative metabolism of ziprasidone. CYP1A2 may contribute to a much lesser extent. Based on in vivo abundance of excretory metabolites, less than one-third of ziprasidone metabolic clearance is mediated by cytochrome P450 catalyzed oxidation and approximately two-thirds via reduction. There are no known clinically relevant inhibitors or inducers of aldehyde oxidase.
Intramuscular PharmacokineticsSystemic Bioavailability: The bioavailability of ziprasidone administered intramuscularly is 100%. After intramuscular administration of single doses, peak serum concentrations typically occur at approximately 60 minutes post-dose or earlier and the mean half-life (T½) ranges from two to five hours. Exposure increases in a dose-related manner and following three days of intramuscular dosing, little accumulation is observed.
Metabolism and Elimination: Although the metabolism and elimination of IM ziprasidone have not been systematically evaluated, the intramuscular route of administration would not be expected to alter the metabolic pathways.
Included as part of the PRECAUTIONS section.
PRECAUTIONS Increased Mortality In Elderly Patients With Dementia-Related PsychosisElderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Zeldox is not approved for the treatment of dementia-related psychosis.
QT Prolongation And Risk Of Sudden DeathZiprasidone use should be avoided in combination with other drugs that are known to prolong the QTc interval. Additionally, clinicians should be alert to the identification of other drugs that have been consistently observed to prolong the QTc interval. Such drugs should not be prescribed with ziprasidone. Ziprasidone should also be avoided in patients with congenital long QT syndrome and in patients with a history of cardiac arrhythmias.
A study directly comparing the QT/QTc prolonging effect of oral ziprasidone with several other drugs effective in the treatment of schizophrenia was conducted in patient volunteers. In the first phase of the trial, ECGs were obtained at the time of maximum plasma concentration when the drug was administered alone. In the second phase of the trial, ECGs were obtained at the time of maximum plasma concentration while the drug was co-administered with an inhibitor of the CYP4503A4 metabolism of the drug.
In the first phase of the study, the mean change in QTc from baseline was calculated for each drug, using a sample-based correction that removes the effect of heart rate on the QT interval. The mean increase in QTc from baseline for ziprasidone ranged from approximately 9 to 14 msec greater than for four of the comparator drugs (risperidone, olanzapine, quetiapine, and haloperidol), but was approximately 14 msec less than the prolongation observed for thioridazine.
In the second phase of the study, the effect of ziprasidone on QTc length was not augmented by the presence of a metabolic inhibitor (ketoconazole 200 mg twice daily).
In placebo-controlled trials, oral ziprasidone increased the QTc interval compared to placebo by approximately 10 msec at the highest recommended daily dose of 160 mg. In clinical trials with oral ziprasidone, the electrocardiograms of 2/2988 (0.06%) patients who received Zeldox and 1/440 (0.23%) patients who received placebo revealed QTc intervals exceeding the potentially clinically relevant threshold of 500 msec. In the ziprasidone-treated patients, neither case suggested a role of ziprasidone. One patient had a history of prolonged QTc and a screening measurement of 489 msec; QTc was 503 msec during ziprasidone treatment. The other patient had a QTc of 391 msec at the end of treatment with ziprasidone and upon switching to thioridazine experienced QTc measurements of 518 and 593 msec.
Some drugs that prolong the QT/QTc interval have been associated with the occurrence of torsade de pointes and with sudden unexplained death. The relationship of QT prolongation to torsade de pointes is clearest for larger increases (20 msec and greater) but it is possible that smaller QT/QTc prolongations may also increase risk, or increase it in susceptible individuals. Although torsade de pointes has not been observed in association with the use of ziprasidone in premarketing studies and experience is too limited to rule out an increased risk, there have been rare post-marketing reports (in the presence of multiple confounding factors).
A study evaluating the QT/QTc prolonging effect of intramuscular ziprasidone, with intramuscular haloperidol as a control, was conducted in patient volunteers. In the trial, ECGs were obtained at the time of maximum plasma concentration following two injections of ziprasidone (20 mg then 30 mg) or haloperidol (7.5 mg then 10 mg) given four hours apart. Note that a 30 mg dose of intramuscular ziprasidone is 50% higher than the recommended therapeutic dose. The mean change in QTc from baseline was calculated for each drug, using a sample-based correction that removes the effect of heart rate on the QT interval. The mean increase in QTc from baseline for ziprasidone was 4.6 msec following the first injection and 12.8 msec following the second injection. The mean increase in QTc from baseline for haloperidol was 6.0 msec following the first injection and 14.7 msec following the second injection. In this study, no patients had a QTc interval exceeding 500 msec.
As with other antipsychotic drugs and placebo, sudden unexplained deaths have been reported in patients taking ziprasidone at recommended doses. The premarketing experience for ziprasidone did not reveal an excess risk of mortality for ziprasidone compared to other antipsychotic drugs or placebo, but the extent of exposure was limited, especially for the drugs used as active controls and placebo. Nevertheless, ziprasidone's larger prolongation of QTc length compared to several other antipsychotic drugs raises the possibility that the risk of sudden death may be greater for ziprasidone than for other available drugs for treating schizophrenia. This possibility needs to be considered in deciding among alternative drug products.
Certain circumstances may increase the risk of the occurrence of torsade de pointes and/or sudden death in association with the use of drugs that prolong the QTc interval, including (1) bradycardia; (2) hypokalemia or hypomagnesemia; (3) concomitant use of other drugs that prolong the QTc interval; and (4) presence of congenital prolongation of the QT interval.
It is recommended that patients being considered for ziprasidone treatment who are at risk for significant electrolyte disturbances, hypokalemia in particular, have baseline serum potassium and magnesium measurements. Hypokalemia (and/or hypomagnesemia) may increase the risk of QT prolongation and arrhythmia. Hypokalemia may result from diuretic therapy, diarrhea, and other causes. Patients with low serum potassium and/or magnesium should be repleted with those electrolytes before proceeding with treatment. It is essential to periodically monitor serum electrolytes in patients for whom diuretic therapy is introduced during ziprasidone treatment. Persistently prolonged QTc intervals may also increase the risk of further prolongation and arrhythmia, but it is not clear that routine screening ECG measures are effective in detecting such patients. Rather, ziprasidone should be avoided in patients with histories of significant cardiovascular illness, e.g., QT prolongation, recent acute myocardial infarction, uncompensated heart failure, or cardiac arrhythmia. Ziprasidone should be discontinued in patients who are found to have persistent QTc measurements > 500 msec.
For patients taking ziprasidone who experience symptoms that could indicate the occurrence of torsade de pointes, e.g., dizziness, palpitations, or syncope, the prescriber should initiate further evaluation, e.g., Holter monitoring may be useful.
Neuroleptic Malignant Syndrome (NMS)A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with administration of antipsychotic drugs. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatinine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.
The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to exclude cases where the clinical presentation includes both serious medical illness (e.g., pneumonia, systemic infection, etc.) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system (CNS) pathology.
The management of NMS should include: (1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; (2) intensive symptomatic treatment and medical monitoring; and (3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for NMS.
If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. The patient should be carefully monitored, since recurrences of NMS have been reported.
Severe Cutaneous Adverse Reactions Drug Reaction With Eosinophilia And Systemic Symptoms (DRESS)Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) has been reported with Ziprasidone exposure. DRESS consists of a combination of three or more of the following: cutaneous reaction (such as rash or exfoliative dermatitis), eosinophilia, fever, lymphadenopathy and one or more systemic complications such as hepatitis, nephritis, pneumonitis, myocarditis, and pericarditis. DRESS is sometimes fatal. Discontinue ziprasidone if DRESS is suspected.
Other Severe Cutaneous Adverse ReactionsOther severe cutaneous adverse reactions, such as Stevens-Johnson syndrome, have been reported with ziprasidone exposure. Severe cutaneous adverse reactions are sometimes fatal. Discontinue ziprasidone if severe cutaneous adverse reactions are suspected.
Tardive DyskinesiaA syndrome of potentially irreversible, involuntary, dyskinetic movements may develop in patients undergoing treatment with antipsychotic drugs. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely to develop the syndrome. Whether antipsychotic drug products differ in their potential to cause tardive dyskinesia is unknown.
The risk of developing tardive dyskinesia and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses.
There is no known treatment for established cases of tardive dyskinesia, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome, and thereby may possibly mask the underlying process. The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown.
Given these considerations, ziprasidone should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. Chronic antipsychotic treatment should generally be reserved for patients who suffer from a chronic illness that (1) is known to respond to antipsychotic drugs, and (2) for whom alternative, equally effective, but potentially less harmful treatments are not available or appropriate. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically.
If signs and symptoms of tardive dyskinesia appear in a patient on ziprasidone, drug discontinuation should be considered. However, some patients may require treatment with ziprasidone despite the presence of the syndrome.
Metabolic ChangesAtypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk. These metabolic changes include hyperglycemia, dyslipidemia, and body weight gain. While all of the drugs in the class have been shown to produce some metabolic changes, each drug has its own specific risk profile.
Hyperglycemia And Diabetes MellitusHyperglycemia and diabetes mellitus, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, have been reported in patients treated with atypical antipsychotics. There have been few reports of hyperglycemia or diabetes in patients treated with Zeldox. Although fewer patients have been treated with Zeldox, it is not known if this more limited experience is the sole reason for the paucity of such reports. Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of diabetes mellitus in patients with schizophrenia and the increasing incidence of diabetes mellitus in the general population. Given these confounders, the relationship between atypical antipsychotic use and hyperglycemia-related adverse reactions is not completely understood. Precise risk estimates for hyperglycemia-related adverse reactions in patients treated with atypical antipsychotics are not available.
Patients with an established diagnosis of diabetes mellitus who are started on atypical antipsychotics should be monitored regularly for worsening of glucose control. Patients with risk factors for diabetes mellitus (e.g., obesity, family history of diabetes) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of antidiabetic treatment despite discontinuation of the suspect drug.
Pooled data from short-term, placebo-controlled studies in schizophrenia and bipolar disorder are presented in Tables 1-4. Note that for the flexible dose studies in both schizophrenia and bipolar disorder, each subject is categorized as having received either low (20-40 mg BID) or high (60–80 mg BID) dose based on the subject's modal daily dose. In the tables showing categorical changes, the percentages (% column) are calculated as 100×(n/N).
Table 1: Glucose* Mean Change from Baseline in Short-Term (up to 6 weeks ), Placebo- Controlled, Fixed-Dose, Oral Ziprasidone, Monotherapy Trials in Adult Patients with Schizophrenia
| Mean Random Glucose Change from Baseline mg/dL (N) | ||||||
| Ziprasidone | Placebo | |||||
| 5 mg BID | 20 mg BID | 40 mg BID | 60 mg BID | 80 mg BID | 100 mg BID | |
| -1.1 (N=45) | +2.4 (N=179) | -0.2 (N=146) | -0.5 (N=119) | -1.7 (N=104) | +4.1 (N=85) | +1.4 (N=260) |
| * “Random” glucose measurements—fasting/non-fasting status unknown |
Table 2: Glucose Categorical Changes in Short-Term (up to 6 weeks ), Placebo-Controlled, Fixed-Dose, Oral Ziprasidone, Monotherapy Trials in Adult Patients with Schizophrenia
| Laboratory Analyte | Category Change (at least once) from Baseline | Treatment Arm | N | n (%) |
| Random Glucose | Normal to High ( < 100 mg/dL to ≥ 126 mg/dL) | Ziprasidone | 438 | 77 (17.6%) |
| Placebo | 169 | 26 (15.4%) | ||
| Borderline to High ( ≥ 100 mg/dL and < 126 mg/dL to ≥ 126 mg/dL) | Ziprasidone | 159 | 54 (34.0%) | |
| Placebo | 66 | 22 (33.3%) | ||
| *“Random” glucose measurements – fasting/non-fasting status unknown |
In long-term (at least 1 year), placebo-controlled, flexible-dose studies in schizophrenia, the mean change from baseline in random glucose for ziprasidone 20-40 mg BID was -3.4 mg/dL (N=122); for ziprasidone 60-80 mg BID was +1.3 mg/dL (N=10); and for placebo was +0.3 mg/dL (N=71).
Table 3: Glucose* Mean Change from Baseline in Short-Term (up to 6 weeks ), Placebo- Controlled, Flexible-Dose, Oral Ziprasidone, Monotherapy Trials in Adult Patients with Bipolar Disorder
| Mean Fasting Glucose Change from Baseline mg/dL (N) | ||
| Ziprasidone | Placebo | |
| Low Dose: 20-40 mg BID | High Dose: 60-80 mg BID | |
| +0.1 (N=206) | +1.6 (N=166) | +1.4 (N=287) |
| *Fasting |
Table 4: Glucose* Categorical Changes in Short-Term (up to 6 weeks), Placebo-Controlled, Flexible-Dose, Oral Ziprasidone, Monotherapy Trials in Adult Patients with Bipolar Disorder
| Laboratory Analyte | Category Change (at least once) from Baseline | Treatment Arm | N | n (%) |
| Fasting Glucose | Normal to High ( < 100 mg/dL to ≥ 126 mg/dL) | Ziprasidone | 272 | 5 (1.8%) |
| Placebo | 210 | 2 (1.0%) | ||
| Borderline to High ( ≥ 100 mg/dL and < 126 mg/dL to ≥ 126 mg/dL) | Ziprasidone | 79 | 12 (15.2%) | |
| Placebo | 71 | 7 (9.9%) | ||
| *Fasting |
Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics. Pooled data from short-term, placebo-controlled studies in schizophrenia and bipolar disorder are presented in Tables 5-8.
Table 5: Lipid* Mean Change from Baseline in Short-Term (up to 6 weeks ), Placebo-Controlled, Fixed-Dose, Oral Ziprasidone Monotherapy Trials in Adult Patients with Schizophrenia
| Mean Lipid Change from Baseline mg/dL (N) | |||||||
| Laboratory Analyte | Ziprasidone | Placebo | |||||
| 5 mg BID | 20 mg BID | 40 mg BID | 60 mg BID | 80 mg BID | 100 mg BID | ||
| Triglycerides | -12.9 (N=45) | -9.6 (N=181) | -17.3 (N=146) | -0.05 (N=120) | -16.0 (N=104) | +0.8 (N=85) | -18.6 (N=260) |
| Total Cholesterol | -3.6 (N=45) | 1) 48 ”I | -8.2 (N=147) | -3.6 (N=120) | -10.0 (N=104) | -3.6 (N=85) | -4.7 (N=261) |
| *“Random” lipid measurements, fasting/non-fasting status unknown |
Table 6: Lipid Categorical Changes in Short-Term (up to 6 weeks), Placebo-Controlled, Fixed-Dose, Oral Ziprasidone Monotherapy Trials in Adult Patients with Schizophrenia
| Laboratory Analyte | Category Change (at least once) from Baseline | Treatment Arm | N | n (%) |
| Triglycerides | Increase by ≥ 50 mg/dL | Ziprasidone | 681 | 232 (34.1%) |
| Placebo | 260 | 53 (20.4%) | ||
| Normal to High ( < 150 mg/dL to ≥ 200 mg/dL) | Ziprasidone | 429 | 63 (14.7%) | |
| Placebo | 152 | 12 (7.9%) | ||
| Borderline to High ( ≥ 150 mg/dL and < 200 mg/dL to ≥ 200 mg/dL) | Ziprasidone | 92 | 43 (46.7%) | |
| Placebo | 41 | 12 (29.3%) | ||
| Total Cholesterol | Increase by ≥ 40 mg/dL | Ziprasidone | 682 | 76 (11.1%) |
| Placebo | 261 | 26 (10.0%) | ||
| Normal to High ( < 200 mg/dL to ≥ 240 mg/dL) | Ziprasidone | 380 | 15 (3.9%) | |
| Placebo | 145 | 0 (0.0%) | ||
| Borderline to High ( ≥ 200 mg/dL and < 240 mg/dL to ≥ 240 mg/dL) | Ziprasidone | 207 | 56 (27.1%) | |
| Placebo | 82 | 22 (26.8%) | ||
| *“Random” lipid measurements, fasting/non-fasting status unknown |
In long-term (at least 1 year), placebo-controlled, flexible-dose studies in schizophrenia, the mean change from baseline in random triglycerides for ziprasidone 20-40 mg BID was +26.3 mg/dL (N=15); for ziprasidone 60-80 mg BID was -39.3 mg/dL (N=10); and for placebo was +12.9 mg/dL (N=9). In long-term (at least 1 year), placebo-controlled, flexible-dose studies in schizophrenia, the mean change from baseline in random total cholesterol for ziprasidone 20-40 mg BID was +2.5 mg/dL (N=14); for ziprasidone 60-80 mg BID was -19.7 mg/dL (N=10); and for placebo was -28.0 mg/dL (N=9).
Table 7: Lipid* Mean Change from Baseline in Short-Term (up to 6 weeks ), Placebo-Controlled, Flexible-Dose, Oral Ziprasidone Monotherapy Trials in Adult Patients with Bipolar Disorder
| Laboratory Analyte | Mean Change from Baseline mg/dL (N) | ||
| Ziprasidone | Placebo | ||
| Low Dose: 20-40 mg BID | High Dose: 60-80 mg BID | ||
| Fasting Triglycerides | +0.95 (N=206) | -3.5 (N=165) | +8.6 (N=286) |
| Fasting Total Cholesterol | -2.8 (N=206) | -3.4 (N=165) | -1.6 (N=286) |
| Fasting LDL Cholesterol | -3.0 (N=201) | -3.1 (N=158) | -1.97 (N=270) |
| Fasting HDL cholesterol | -0.09 (N=206) | +0.3 (N=165) | -0.9 (N=286) |
| *Fasting |
Table 8: Lipid* Categorical Changes in Short-Term (up to 6 weeks ), Placebo-Controlled, Flexible-Dose, Oral Ziprasidone Monotherapy Trials in Adult Patients with Bipolar Disorder
| Laboratory Analyte | Category Change (at least once) from Baseline | Treatment Arm | N | n (%) |
| Fasting Triglycerides | Increase by ≥ 50 mg/dL | Ziprasidone | 371 | 66 (17.8%) |
| Placebo | 286 | 62 (21.7%) | ||
| Normal to High ( < 150 mg/dL to ≥ 200 mg/dL) | Ziprasidone | 225 | 15 (6.7%) | |
| Placebo | 179 | 13 (7.3%) | ||
| Borderline to High ( ≥ 150 mg/dL and < 200 mg/dL to ≥ 200 mg/dL) | Ziprasidone | 58 | 16 (27.6%) | |
| Placebo | 47 | 14 (29.8%) | ||
| Fasting Total Cholesterol | Increase by ≥ 40 mg/dL | Ziprasidone | 371 | 30 (8.1%) |
| Placebo | 286 | 13 (4.5%) | ||
| Normal to High ( < 200 mg/dL to ≥ 240 mg/dL) | Ziprasidone | 204 | 5 (2.5%) | |
| Placebo | 151 | 2 (1.3%) | ||
| Borderline to High ( ≥ 200 mg/dL and < 240 mg/dL to ≥ 240 mg/dL) | Ziprasidone | 106 | 10 (9.4%) | |
| Placebo | 87 | 15 (17.2%) | ||
| Fasting LDL Cholesterol | Increase by ≥ 30 mg/dL | Ziprasidone | 359 | 39 (10.9%) |
| Placebo | 270 | 17 (6.3%) | ||
| Normal to High ( < 100 mg/dL to ≥ 160 mg/dL) | Ziprasidone | 115 | 0 (0%) | |
| Placebo | 89 | 1 (1.1%) | ||
| Borderline to High ( ≥ 100 mg/dL and < 160 mg/dL to ≥ 160 mg/dL) | Ziprasidone | 193 | 18 (9.3%) | |
| Placebo | 141 | 14 (9.9%) | ||
| Fasting HDL | Normal ( > =40 mg/dL) to Low ( < 40 mg/dL) | Ziprasidone | 283 | 22 (7.8%) |
| Placebo | 220 | 24 (10.9%) | ||
| *Fasting |
Weight gain has been observed with atypical antipsychotic use. Monitoring of weight is recommended. Pooled data from short-term, placebo-controlled studies in schizophrenia and bipolar disorder are presented in Tables 9-10.
Table 9: Weight Mean Changes in Short-Term (up to 6 weeks ), Placebo-Controlled, Fixed-Dos e, Oral Zipras idone Monotherapy Trials in Adult Patients with Schizophrenia
| Ziprasidone | Placebo | |||||
| 5 mg BID | 20 mg BID | 40 mg BID | 60 mg BID | 80 mg BID | 100 mg BID | |
| Mean Weight (kg) Changes from Baseline (N) | ||||||
| +0.3 (N=40) | +1.0 (N=167) | +1.0 (N=135) | +0.7 (N=109) | +1.1 (N=97) | +0.9 (N=74) | -0.4 (227) |
| Proportion of Patients with ≥ 7% Increase in Weight from Baseline (N) | ||||||
| 0.0% (N=40) | 9.0% (N=167) | 10.4% (N=135) | 7.3% (N=109) | 15.5% (N=97) | 10.8% (N=74) | 4.0% (N=227) |
In long-term (at least 1 year), placebo-controlled, flexible-dose studies in schizophrenia, the mean change from baseline weight for ziprasidone 20-40 mg BID was -2.3 kg (N=124); for ziprasidone 60-80 mg BID was +2.5 kg (N=10); and for placebo was -2.9 kg (N=72). In the same long-term studies, the proportion of subjects with ≥ 7% increase in weight from baseline for ziprasidone 20-40 mg BID was 5.6% (N=124); for ziprasidone 60-80 mg BID was 20.0% (N=10), and for placebo was 5.6% (N=72). In a long-term (at least 1 year), placebo-controlled, fixed-dose study in schizophrenia, the mean change from baseline weight for ziprasidone 20 mg BID was -2.6 kg (N=72); for ziprasidone 40 mg BID was - 3.3 kg (N=69); for ziprasidone 80 mg BID was -2.8 kg (N=70) and for placebo was -3.8 kg (N=70). In the same long-term fixed-dose schizophrenia study, the proportion of subjects with ≥ 7% increase in weight from baseline for ziprasidone 20 mg BID was 5.6% (N=72); for ziprasidone 40 mg BID was 2.9% (N=69); for ziprasidone 80 mg BID was 5.7% (N=70) and for placebo was 2.9% (N=70).
Table 10: Summary of Weight Change in Short-Term (up to 6 weeks), Placebo-Controlled, Flexible-Dose, Oral Ziprasidone Monotherapy Trials in Adult Patients with Bipolar Disorder:
| Ziprasidone | Placebo | |
| Low Dose: 20-40 mg BID | High Dose*: 60-80 mg BID | |
| Mean Weight (kg) Changes from Baseline (N) | ||
| +0.4 (N=295) | +0.4 (N=388) | +0.1 (N=451) |
| Proportion of Patients with ≥ 7% Increase in Weight from Baseline (N) | ||
| 2.4% (N=295) | 4.4% (N=388) | 1.8% (N=451) |
| *Note that in the High Dose group, there were 2 subjects with modal 200 mg total daily dose and 1 subject with modal 100 mg total daily dose. | ||
The proportions of patients meeting a weight gain criterion of ≥ 7% of body weight were compared in a pool of four 4- and 6-week placebo-controlled schizophrenia clinical trials, revealing a statistically significantly greater incidence of weight gain for ziprasidone (10%) compared to placebo (4%). A median weight gain of 0.5 kg was observed in ziprasidone patients compared to no median weight change in placebo patients. In this set of clinical trials, weight gain was reported as an adverse reaction in 0.4% and 0.4% of ziprasidone and placebo patients, respectively. During long-term therapy with ziprasidone, a categorization of patients at baseline on the basis of body mass index (BMI) revealed the greatest mean weight gain and highest incidence of clinically significant weight gain ( > 7% of body weight) in patients with low BMI ( < 23) compared to normal (23–27) or overweight patients ( > 27). There was a mean weight gain of 1.4 kg for those patients with a “low” baseline BMI, no mean change for patients with a “normal” BMI, and a 1.3 kg mean weight loss for patients who entered the program with a “high” BMI.
Bipolar DisorderDuring a 6-month placebo-controlled bipolar maintenance study in adults with ziprasidone as an adjunct to lithium or valproate, the incidence of clinically significant weight gain ( ≥ 7% of body weight) during the double-blind period was 5.6% for both ziprasidone and placebo treatment groups who completed the 6 months of observation for relapse. Interpretation of these findings should take into consideration that only pat
Zeldox Capsules should be administered at an initial daily dose of 20 mg twice daily with food. In some patients, daily dosage may subsequently be adjusted on the basis of individual clinical status up to 80 mg twice daily. Dosage adjustments, if indicated, should generally occur at intervals of not less than 2 days, as steady-state is achieved within 1 to 3 days. In order to ensure use of the lowest effective dose, patients should ordinarily be observed for improvement for several weeks before upward dosage adjustment.
Efficacy in schizophrenia was demonstrated in a dose range of 20 mg to 100 mg twice daily in shortterm, placebo-controlled clinical trials. There were trends toward dose response within the range of 20 mg to 80 mg twice daily, but results were not consistent. An increase to a dose greater than 80 mg twice daily is not generally recommended. The safety of doses above 100 mg twice daily has not been systematically evaluated in clinical trials.
Maintenance TreatmentWhile there is no body of evidence available to answer the question of how long a patient treated with ziprasidone should remain on it, a maintenance study in patients who had been symptomatically stable and then randomized to continue ziprasidone or switch to placebo demonstrated a delay in time to relapse for patients receiving Zeldox. No additional benefit was demonstrated for doses above 20 mg twice daily. Patients should be periodically reassessed to determine the need for maintenance treatment.
Bipolar I Disorder (Acute Mixed Or Manic Episodes And Maintenance Treatment As An Adjunct To Lithium Or Valproate) Acute Treatment Of Manic Or Mixed EpisodesDose Selection-Oral ziprasidone should be administered at an initial daily dose of 40 mg twice daily with food. The dose may then be increased to 60 mg or 80 mg twice daily on the second day of treatment and subsequently adjusted on the basis of tolerance and efficacy within the range 40 mg–80 mg twice daily. In the flexible-dose clinical trials, the mean daily dose administered was approximately 120 mg.
Maintenance Treatment (as an adjunct to lithium or valproate)Continue treatment at the same dose on which the patient was initially stabilized, within the range of 40 mg–80 mg twice daily with food. Patients should be periodically reassessed to determine the need for maintenance treatment.
Acute Treatment Of Agitation In Schizophrenia Intramuscular DosingThe recommended dose is 10 mg to 20 mg administered as required up to a maximum dose of 40 mg per day. Doses of 10 mg may be administered every two hours; doses of 20 mg may be administered every four hours up to a maximum of 40 mg/day. Intramuscular administration of ziprasidone for more than three consecutive days has not been studied.
If long-term therapy is indicated, oral ziprasidone hydrochloride capsules should replace the intramuscular administration as soon as possible.
Since there is no experience regarding the safety of administering ziprasidone intramuscular to schizophrenic patients already taking oral ziprasidone, the practice of co-administration is not recommended.
Ziprasidone intramuscular is intended for intramuscular use only and should not be administered intravenously.
Intramuscular Preparation For AdministrationZeldox for Injection (ziprasidone mesylate) should only be administered by intramuscular injection and should not be administered intravenously. Single-dose vials require reconstitution prior to administration.
Add 1.2 mL of Sterile Water for Injection to the vial and shake vigorously until all the drug is dissolved. Each mL of reconstituted solution contains 20 mg ziprasidone. To administer a 10 mg dose, draw up 0.5 mL of the reconstituted solution. To administer a 20 mg dose, draw up 1.0 mL of the reconstituted solution. Any unused portion should be discarded. Since no preservative or bacteriostatic agent is present in this product, aseptic technique must be used in preparation of the final solution. This medicinal product must not be mixed with other medicinal products or solvents other than Sterile Water for Injection. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Dosing In Special Populations OralDosage adjustments are generally not required on the basis of age, gender, race, or renal or hepatic impairment. Zeldox is not approved for use in children or adolescents.
IntramuscularZiprasidone intramuscular has not been systematically evaluated in elderly patients or in patients with hepatic or renal impairment. As the cyclodextrin excipient is cleared by renal filtration, ziprasidone intramuscular should be administered with caution to patients with impaired renal function. Dosing adjustments are not required on the basis of gender or race.
